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Mapping tumor hypoxia is a great challenge in positron emission tomography (PET)
imaging as the precise functional information of the biological processes is needed for
many effective therapeutic strategies. Tumor hypoxia has been widely reported as a
poor prognostic indicator and is often associated with tumor aggressiveness, chemo-
and radio-resistance. An accurate diagnosis of hypoxia is a challenge and is crucial for
providing accurate treatment for patients’ survival benefits. This challenge has led to the
emergence of new and novel PET tracers for the functional andmetabolic characterization
of tumor hypoxia non-invasively. Among these tracers, copper semicarbazone compound
[64Cu]-diacetyl-bis(N4-methylthiosemicarbazone) (=64Cu-ATSM) has been developed
as a tracer for hypoxia imaging. This review focuses on 64Cu-ATSM PET imaging
and the concept is presented in two sections. The first section describes its in vitro
development and pre-clinical testing and particularly its affinity in different cell lines. The
second section describes the controversial reports on its specificity for hypoxia imaging.
The review concludes that 64Cu-ATSM – more than a hypoxic tracer, exhibits tracer
accumulation in tumor, which is linked to the redox potential and reactive oxygen species.
The authors concluded that 64Cu-ATSNM is a marker of over-reduced cell state and
thus an indirect marker for hypoxia imaging. The affinity of 64Cu-ATSM for over-reduced
cells was observed to be a complex phenomenon. And to provide a definitive and
convincing mechanism, more in vivo studies are needed to prove the diagnostic utility of
64Cu-ATSM.
Keywords: cancer, [64Cu]-ATSM, hypoxia, positron emission tomography, reactive oxygen species,
radiopharmaceutical
Introduction
Tumor hypoxia is a common and important feature of the tumoral microenvironment, and a
well-known consequence of an inadequate supply of dioxygen (O2) in a wide range of malignant
solid tumors. This hypoxic phenomenon is mainly linked to the imbalance between the high rate
of cell proliferation potential during the carcinogenesis process compared to the more slower
neoangiogenesis. Despite the difference between biochemists (O 2 limited electron transport in
mitochondria) and physiologists (reduced O2 availability due to a decreased O2 partial pressure)
definition, the hypoxia clinical aspect with a limited oxygen delivery to the aerobic neoplastic and
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stromal cells is frequently observed in various tumor type with
very low oxygen levels where the partial pressure in oxygen is <5
versus 40–60mmHg in normal tissues (1).
The origin of hypoxia regions in human tumors was postulated
by Thomlinson and Gray in 1955s with some observation based
on the diminution of the oxygen diffusion with the blood supply
distance (2). This limited diffusion of oxygen at distance (about
100µm) of capillary blood vessels is at the origin of a chronic dif-
fusion hypoxia. In parallel, an acute perfusion hypoxia closest to
the capillary vessel was observed. This acute event was the conse-
quence of functionally and structurally defective vascular network
in tumor (overdilated, hyperpermeable, tortuous, and disrupted),
combined with the high-interstitial pressure of the extracellular
matrix, which compress the vessel and reduce the blood flow.
From physiopathological aspect, hypoxia is heterogenous in
time and in space and not only accounts for tissue necrosis
but also a strong impact on tumor biology and has several bad
pronostic for patient clinical outcome. In fact, during the tumor
malignant growth, hypoxic area is correlated with an increased
genetic instability and more aggressive phenotype which conduct
to a strongly associated tumor metastasis risk. Likewise, hypoxia
causes unequivocally some resistances to cancers treatments. It
has been known from many years that hypoxic condition could
cause an intrinsic chemoresistance (by different mechanisms like
diminution of the drug concentration in relation with the blood
vessel distance, loss of sensitivity to p53-mediated apoptosis, or
diminution of cell proliferation by metabolic stress) and generate
a resistance to killing by ionizing radiation [diminution of the free
radical damage on the intracellular reactive oxygen species (ROS)
during hypoxia event].
During 1990s, interest in overcoming the problem of the radi-
ation resistance of hypoxic cells in tumors was rekindled by the
use of commercially available oxygen electrode (mostly known as
“Eppendorf electrode”), which permit to measure oxygen partial
pressure levels (pO2) in human tumors. However, this method
presents somemajor drawbacks because it is an invasive technique
limited to accessible tumors with sufficient size with a risk of
tissue disruption and is known to present a large inter-observer
variability. In addition to this direct measurement of pO2, an
other invasive method based on biopsy coupled to cytological
coloration with nitroimidazole compounds (like pimonidazole
or EF5) or coupled to immunohistochemical analysis of vari-
ous hypoxia markers proteins [like hypoxia inducing factors-1α
(HIF-1α) or carbonic anhydrase IX (CAIX)]. In recent decades,
investigations into alternative, non-invasive imaging methods
for measuring pO2 have been studied and the use of positron
emission tomography (PET) has led to a number of promis-
ing positron emitters radiopharmaceuticals. Among the different
tumor hypoxia PET radiotracers, the innovative [64Cu]-diacetyl-
bis(N4-methylthiosemicarbazone) (=[64Cu]-ATSM) presented in
Figure 1 raises questions about its real target in tumor hypoxia
process and presents some controversial aspects.
Cu-ATSM In vitro Results
An ideal hypoxia imaging agent should have a high membrane
permeability for easy access to intracellular mitochondria and a
FIGURE 1 | [64Cu]-diacetyl-bis(N4-methylthiosemicarbazone)
(=64Cu-ATSM).
low redox potential to confer stability in normal tissue, but it
should be able to be reduced by mitochondria with abnormally
high electron concentrations in hypoxic cells. After numerous
studies on nitroimidazole compounds for their selective accumu-
lation in hypoxic tumors, as well as in ischemic tissue (3, 4), Cu-
ATSM a lipophilic molecule, with high membrane permeability
and low redox potential, was presented by Fujiyabashi et al. as
a possible hypoxia imaging agent in occluded rat heart model
(5). Cu-ATSM was reduced by hypoxic but not by normal mito-
chondria and Cu-ATSM retention was inversely correlated with
accumulation of 201TI, a relative myocardial blood flow marker.
Different schemas were proposed in the literature (6–8) but, to
date, there is a consensus that in vitroCu-ATSM undergoes biore-
ductive trapping under hypoxic conditions. After cellular entry,
Cu(II)-ATSM is reduced to an unstable Cu(I)-ATSM species, a
process inducing dissociation of the metal complex and subse-
quent irreversible trapping of Cu(I) within the cellular copper
metabolic processes (9). A simplified mechanism of the reaction
of Cu(II)-ATSM with cells reported that the lipophilic molecule
may be diffuse into the cells by combined passive and facilitated
(protein-carrier-mediated) mechanisms with no evidence to sup-
port a role for copper-transporter 1 (Ctr1) in accumulation of the
compound (10). In hypoxic cells, Cu-ATSM reacted with thiol
groups or redox-active proteins with NADH as a required enzy-
matic cofactor. The reduced, charged form is less lipophilic and
retained in the cell, providing opportunity for it to be reoxidized
in the normoxic cell (11). Protonation of the reduced form at
the N3 and N6 positions will lead to the complex dissociating
and the copper will be irreversibly trapped in the hypoxic cell
(Figure 2). R could be a thiol, such as glutathione, or a thiol
group of a redox-active protein. Cellular trapping of the copper
is dependent on oxygen, pH, and NADH (12). Early on, Burgman
et al. indicated considerable variation in 64Cu accumulation fol-
lowing incubation with 64Cu-ATSM among different cell lines
(prostate carcinoma, fibrosarcoma, breast adenocarcinoma, and
squamous cell carcinoma) with regard to uptake kinetics, max-
imum accumulation, and their dependence on oxygen condi-
tions (8).
Recently, different authors explored the relationship between
Cu-ATSM and some characteristics of cancer cells. First, Liu
et al. showed that in vitro cells highly expressing multi-drug
resistance (MDR1) had significantly decreased Cu-ATSM reten-
tion and enhanced efflux. Knockdown of MDR1 expression sig-
nifipcantly enhanced the Cu-ATSM retention and decreased the
efflux in MDR1-positive cells (13). Then, Yoshii et al. showed that
64Cu-ATSM accumulated in rich regions of CD133+ cells with
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FIGURE 2 | Overview of the cellular 64Cu-ATSM uptake and retention mechanisms. In hypoxic condition, the Cu(II)-ATSM (oxidation level of copper-64 is +II)
is reduced to Cu(I)-ATSM (oxidation level of copper-64 is +I) then the complex became instable and free copper-64 is trapped and accumulate in intracellular copper
chaperones proteins.
characteristics of cancer stem cells. Therefore, 64Cu-ATSM could
be a potential imaging or therapy agent for rich regions ofCD133+
cells, associated with cancer stem cells, within tumors (14). The
same team was interested in the evaluation of Cu-ATSM as an
indicator of intracellular overreduced states in mitochondrial
disorders using cell lines with mitochondrial dysfunction, even
under normoxia. Study results showed that Cu-ATSM would be a
promisingmarker of intracellular overreduced states for disorders
with mitochondrial dysfunction, such as Parkinson’s disease and
Alzheimer disease (15).
Still on the fact that Cu-ATSM is not a PET hypoxia marker
in all tumors, Vavere et al. focused on the relationship between
Cu-ATSM hypoxia and fatty acid synthase (FAS) expression in
prostate cancer cell lines (16). The physiological significance of
the fatty acid synthesis pathway in prostate cancers is in the
harnessing of its oxidizing power for improving redox balance (i.e.,
lower NADH/NAD+ ratios) despite oxygen-limiting (hypoxic)
conditions. This team demonstrated that in the FAS tumor line,
the lower-than-average redox potential caused reduction and
trapping of Cu-ATSM in both hypoxic and normoxic areas (16).
Then, Cu-ATSM translation to the hypoxia imaging of prostate
cancer may be limited by the overexpression of FAS associated
with prostatic malignancies.
Cu-ATSM In vivo Results
The current knowledge on the tumor microenvironment shows
a great number of metabolic circumstances and therefore a high
variability in hypoxia tumor status with different physiopatholog-
ical process.
One of the first 64Cu-ATSMpre-clinical study in tumor hypoxia
imaging has used a mice bearing EMT6 breast carcinoma cell
line, which has shown an heterogeneous uptake of the radio-
tracer (intense uptake was observed in 15–30% of the tumor)
supposed to be correlated with the hypoxic area of the tumor
(11). Other pre-clinical study in tumor hypoxia imaging has used
an epidermoid rabbit tumor, which is known to present a high
glycolytic/high hexokinase rate with high anaerobic glycolysis
pathway (high lactic acid production and high NADPH ratio)
(17). This study showed a major accumulation of 64Cu-ATSM
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around the outer rim of the tumor masses where the histological
cell biology showed active, viable, and expected hypoxic cells (18).
More recently, the affinity of 64Cu-ATSM for viable and hypoxic
cells was confirmed with the comparison of the regional dis-
tribution between 64Cu-ATSM and other prominent radiophar-
maceuticals in tumor metabolic status determination field: 18F-
MISO, 18F-FLT, and 18F-FDG. The characterization of the in vivo
behavior of 64Cu-ATSM indicate a very strong correlation with
classical hypoxia (18F-MISO) and proliferation (18F-FLT) PET
radiotracer (r2= 0.864 and 0.829, respectively) but not correlate
with the 18F-FDG metabolic PET radiotracer (r2= 0.08) (19).
In the same way, a rat graft tumor model of prostate adenocar-
cinoma and human squamous cell carcinoma showed a good cor-
relation between the uptake of 18F-MISO and 64Cu-ATSM when
imaged at later times after injection (20). Effectively, it appeared
that the intratumoral distribution of 64Cu-ATSM exhibited a sig-
nificant evolution between the early (1–2 h after injection) and late
(16–20 h after injection) imaging time. An additional experience
with direct pO2 measurement was broadly consistent with the
hypothesis that the spatial distribution of 18F-MISO and 64Cu-
ATSM at later times reflected tumor hypoxia. A similar study
indicated that for early images, the distribution of Cu-ATSM was
inconsistent with tumor hypoxia and might be more represen-
tative of perfusion. Only at later times after Cu-ATSM adminis-
tration (16–24 h postinjection), the 18F-FMISO and 64Cu-ATSM
images corresponded. Authors did not dispute the potential utility
of Cu-ATSM imaging as a tool in clinical management but for the
first time, they pointed out that its uptake on hypoxic tumor was
unclear (8). In the same way, a more recent study of McCall et al.
tried to determine the pharmacokinetic behavior of 64Cu-ATSM
in combination with microscopic markers of hypoxia. The results
of this study confirmed a rapid tumor uptake and retention of
64Cu-ATSM (tumor-to-muscle ratio was 4:1 within 20min after
injection) with a strong positive spatial correlation to the highly
perfused areas. At late time (18 h post injection), the tumor-to-
muscle ratio was 12:1 and there was no spatial correlation with
the perfused areas (21).
Furthermore, this time-dependent spatial distribution of 64Cu-
ATSM seemed to have retention variability in function of the
tumor cell line. Briefly, a pre-clinical rat model was used and
different tumor lines showed that 64Cu-ATSM was a valid PET
hypoxia marker (correlation of the autoradiographic distribu-
tions with hypoxia markers as EF5, pimonidazole, and CAIX)
for adenocarcinoma and glioma tumor cell line but a hypoxia-
independent uptake of 64Cu-ATSM in fibrosarcoma was observed
(22). Cell-dependent distribution and retention kinetics of Cu-
ATSM are confirmed and underline the need for proper vali-
dation of animal models and PET acquisition protocols before
exploration of any new clinical applications (23). This notion has
recently been confirmed by Carlin et al., who showed that Cu-
ATSM had the highest tumor accumulation and low renal clear-
ance compared to fluorinated nitroimidazoles. However, the lack
of correlation between Cu-ATSM distribution and immunohisto-
chemistry hypoxiamarkers also casted some doubt on the hypoxia
selectivity of Cu-ATSM (24). The suggested reason for the low
correlation between Cu-ATSM uptake and hypoxic distribution,
in some tumors, was the differing redox status of the tumor types.
Some of tumors might have a lower than-average redox poten-
tial with high concentrations of electron donors caused reduc-
tion and trapping of Cu-ATSM in both hypoxic and normoxic
areas. Moreover, in vivo, in two different tumor types, Hueting
et al. demonstrated that the distribution of radiocopper from Cu-
ATSM in tumors essentially mirrors Cu-acetate suggesting that
copper metabolism might also played a role in the mechanism
of selectivity of Cu-ATSM (25). The mechanism of radiolabeled
Cu-ATSM accumulation in hypoxic tumor area was currently
under investigation but it was well-known than there was a high
physiological accumulation of free 64Cu in non-target organ and
the liver was reported to be the principal dose-limiting organ (26).
To reduce the liver absorbed dose, Yoshii et al. showed that the use
of a copper chelator like penicillamine could reduce liver absorbed
dose (increase of free copper renal clearance) but have no effect on
the Cu-ATSM tumor accumulation (27).
In 2008, a clinical use of Cu-ATSM in cancer of the uter-
ine cervix in 10 women permits to obtain high-quality images
(high tumor-to-muscle ratio), which correlate with prognosis and
patients outcome. Importantly, in this study, the uptake pattern
was similar on the images obtainedwith two different imaging ses-
sions 1–9 days apart, indicating that the microscopic distribution
of chronic hypoxia did not change greatly over this interval (28).
Discussion/Conclusion
64Cu-ATSM is a radiopharmaceutical developed for PET imaging
and presented as a complex with high membrane permeability
and low redox potential, ideal for hypoxia imaging. In theory,
low redox potential helped to confer stability in normal tissue
and led reduction bymitochondria with abnormally high electron
concentrations in hypoxic cells.
During the in vivo biodistribution, 64Cu-ATSM is known to
present a high binding ratio to the serum proteins like albumin
(approximately 95% for human, mouse, and rat) (29). The cellu-
lar uptake data of 64Cu-ATSM suggested by various study show
a combined passive diffusion and facilitated (protein-carrier-
mediated) penetrationmechanisms (10). In particular, organs like
liver, the 64Cu-ATSM complex is metabolized and free copper
released follow its own metabolism with a high fixation on hep-
atobiliary tractus (30). This metabolic pathway could also occur
in tumor cells and could explain the variable time-dependent
spatial distribution in hypoxic tumors. From this physiological
metabolism of copper, it appears than free copper present a nega-
tive impact on the PET image information of 64Cu-ATSM. Never-
theless, this impact could be decreased by the co-administration
of -penicillamine, which will permit to accelerate the elimina-
tion of free copper without impact on the 64Cu-ATSM tumor
fixation (27).
64Cu-ATSM has been examined in various in vitro and in vivo
pre-clinical models and presented some variability for in vivo
hypoxia mapping (mainly in term of cell line type and in term
of acquisition time after injection). This heterogeneity in 64Cu-
ATSM uptake led to a complicated interpretation of tumor
hypoxia mapping, and there is a need to determine what extent
radiotracer distribution is important, defined by perfusion (early
time) or by pO2 level (late time).
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FIGURE 3 | Overproduction of reductive species (NADPH and NADH) in
mitochondria during hypoxia. Under normoxia, NADH produced during the
tricarboxylic acid (TCA) cycle are reduced in NAD+ and the respiratory chain
drove the electron (dash arrow) to dioxygen with a proton flux on the
intermembrane space whose flow back on the mitochondrial matrix by the ATP
synthase produced ATP. During hypoxia, the respiratory chain is inhibited and
we observe an accumulation of overreduced species (NADH and NADPH) and a
diminution (in long-term) of ROS production.
In hypoxia biochemical pathway, the intracellular redox poten-
tial becoming progressively more reductive – this agreed with
the observation that hypoxia induced a metabolic switch, which
led to an increase (Figure 3) in the production of NADH and
NADPH (the primary electron donors of the cell). This mod-
ification of the NADH/NAD+ and NADPH/NADP+ ratio in
favor of reductive species (confirmed with the use of rotenone,
a complex 1-inhibitor in mitochondria electron transport chain)
seemed to be at the origin of the Cu-ATSM increased uptake
in normoxic cells (15). Indeed, a disturbed electron flow in the
electron transport chain, by inhibition of complex 1, caused
reduction of Cu(II) to Cu(I) trapped in cells and fourfold higher
reduction of Cu-ATSM was observed in normoxic cells treated
with rotenone. Yoshii et al. deduced the supposed mechanism
of Cu-ATSM retention in hypoxic cells: mitochondrial dysfunc-
tion chain (artificial or as result of hypoxia) caused an excess
of electrons, and therefore, an over-reduced state in cells. Obata
et al. also studied Cu-ATSM retention mechanism (18). They
found some contribution of enzymes, in particular, NADH-
cytochrome b5 reductase and NADPH-cytochrome p450 reduc-
tase. In addition, those enzymatic reductions were enhanced by
induction of hypoxia. Ability in reduction was very sensitive and
dependent of electron donors that are NADH or NADPH. They
found that Cu(II) reduction depended on presence of NADH
and NADPH in cells. More information on hypoxia, Cu-ATSM
might appear to provide information on reductive enzyme expres-
sion and species in cells. Moreover, literature highlighted an
increase of NADH concentration in hypoxic tissue (31). Finally,
there was a strong link between hypoxia and redox potential
in cells. Yoshii et al. also studied Cu-ATSM based on mito-
chondrial dysfunction models, including MELAS mitochondrial
DNA mutation and cells depleted of mitochondrial DNA; their
hypothesis was based on mitochondrial dysfunction and over-
reduced state in cells (15). In their study, Cu-ATSM accumu-
lated in cells, which had a strong reducing potential, includ-
ing normoxic cells, with very strong correlation with rate of
NADH and NADPH. Authors suggested that Cu-ATSM could be
an agent indicator of over-reduced intracellular state generated
by increase of NADH and NADPH levels, including normoxic
cells. Cu-ATSM seemed to be more than hypoxia agent, even if
redox state and hypoxia were both related and dependent phe-
nomena. This data would explain uptake variations according
to cell types (8, 13, 16) and an explication of the low uptake
of certain prostate tumor which overexpressed the FAS because
this enzyme required a large amount of NADPH as cofactor for
function. As previously described, impairment of the respira-
tory chain generated in a first time excessed electrons, which
caused a quickly over-reduced intracellular state, which caused
in first time a generation of ROS, increasing oxidative stress and
damaging surrounding cells. This overproduction of ROS from
mitochondria (32) leads to an oxidative stress in a tumor, which
becomes hypoxic (33). In second time, this oxidative stress medi-
ated the shift in oxidative phosphorylation to anaerobic glycolysis
(down-regulation of mitochondria mediated by HIF, the major
chronic mechanism of hypoxia adaptation in cells) to decrease
ROS levels (34).
Finally, 64Cu-ATSM seemed to be a marker of the over-reduced
cell state and consequently an indirect marker of the hypoxia.
In fact, during a severe and chronic hypoxia, the over-reduced
cell state conduced to a down-regulation of the mitochondria
oxidative phosphorylation and had for consequence a diminu-
tion of intracellular ROS. This affinity of Cu-ATSM for over-
reduced cell was a complex phenomenon with various possibility
of adaptive tumor cells response. To provide a direct answer to
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radiation oncologists (35) requirement, more studies were needed
to determine whether the Cu-ATSM uptake was linked to the low
ROS level in cell. Moreover, the first clinical studies has shown a
predictive response to traditional cancer therapies in patients with
rectal (36), lung (37), and uterine cervix cancer (28, 38) where
Cu-ATSM uptake was of worse prognosis.
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